The company is not profitable yet but is guiding to be profitable in 2024. And revenue is increasing at an impressive pace. The stock doesn't get much analyst attention, but the four analysts that have issued a rating give MVST a consensus price target of $4.50, an 857% gain from its closing price on June 12, 2024. Source: PopTika / Shutterstock.com But all it takes is one. And that's also the number of candidates in Gossamer Bio's pipeline. The company has a candidate, Seralutinib (GB002), in a Phase 3 cli ...

Gossamer Bio Announces First Quarter 2024 Financial Results and Provides Business Update SAN DIEGO—(BUSINESS WIRE)— May 7, 2024 — Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced its financial results for the first quarter ended March 31, 2024 and provided a busine ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q _________________________ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________to_________. Commission File Number: 001-38796 GOSSAMER BIO, INC. (Exact name of Registrant as specified in its charter) ...

Gossamer Bio (GOSS) M&A Announcement May 06, 2024 08:30 AM ET Speaker0 Good morning, ladies and gentlemen, and welcome to the Gossamer Bio Announcement Presentation. I will now turn the presentation over to Brian Dorado. Speaker1 Thank you, operator, and thank you all for joining us on this momentous morning for Gossamer in the field of pulmonary hypertension drug development. Before we begin, please note that certain information discussed on the call today is covered under the Safe Harbor provision of the ...

Strategic collaboration to leverage Chiesi's legacy of respiratory leadership and Gossamer Bio's development expertise in pulmonary hypertension. Gossamer to receive $160 million development reimbursement payment and eligible to receive up to $146 million in regulatory and $180 million in sales milestones. 50/50 commercial profit split in US and global development cost sharing arrangement. Chiesi obtains exclusive ex-US development, manufacturing, and commercial rights, with Gossamer to receive mid-to-high ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 __________________________________________________________________________________ FORM 10-K __________________________________________________________________________________ ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-38796 _____ ...

Exhibit 99.1 Gossamer Bio Announces Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update - First PAH Patient Dosed in Ongoing Registrational Phase 3 PROSERA Study - - Inclusion of Japan in Phase 3 PROSERA Study Following CTN Acceptance by PMDA - - Cash, cash equivalents and marketable securities totaled $296 million at year-end 2023 - SAN DIEGO — (BUSINESS WIRE) — March 5, 2024 — Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the developm ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q _________________________ For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________to_________. Commission File Number: 001-38796 GOSSAMER BIO, INC. (Exact name of Registrant as specified in its charter). _________________________ Delaware 47-5461709 (State or other jurisdiction of inc ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q _________________________ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________to_________. Commission File Number: 001-38796 GOSSAMER BIO, INC. (Exact name of Registrant as specified in its charte ...

Table of Contents WASHINGTON, D.C. 20549 _________________________ FORM 10-Q _________________________ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________to_________. Commission File Number: 001-38796 GOSSAMER BIO, INC. (Exact name of Registrant ...